Form 4: Cingulate Inc. Executive Acquires Stock Options

Raul R. Silva, EVP and CSO of Cingulate Inc., reports the acquisition of stock options.

Summary

• Raul R. Silva, the EVP and CSO of Cingulate Inc. (CING), filed a Form 4 with the SEC.
• The form reports a transaction that occurred on June 28, 2024.
• Silva acquired 1,000 stock options with an exercise price of $0.32.
• The options were granted pursuant to the terms of Dr. Silva's Employment Agreement, as amended.
• The options are exercisable from June 28, 2024, and expire on June 28, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a routine disclosure of stock option grants to an executive, which is a common practice.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Management Comments

• The option was granted pursuant to the terms of Dr. Silva's Employment Agreement, as amended.

Industry Context

Executive compensation packages often include stock options to align the interests of management with those of shareholders. This grant is a standard component of such packages.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical industry, often benchmarked against peer companies of similar size and stage of development.
• Companies like Neos Therapeutics and Supernus Pharmaceuticals also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of the shareholders, potentially incentivizing him to increase shareholder value.

Key Dates

Keywords

Stock Options, Form 4, Cingulate Inc., Executive Compensation, Beneficial Ownership, Securities, Silva, CING